Close
ACHEMA MIDDLE EAST 2026
LogiPharma 2026

Clinical Trials

Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease

Clinical Trials
Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and Nonalcoholic Steatohepatitis (NASH), announced...

Optimismm of POMALYST omit positive results for treating a malicious disease: Celegne corporation

Clinical Trials
SMM evaluated the efficacy and safety of POMALYST/IMNOVID (pomalidomide) plus bortezomib and low-dose dexamethasone (PVd) versus bortezomib and low-dose dexamethasone in patients with relapsed/refractory...

Roche’s TECENTRIQ®and Avastin® reduced the risk of disease worsening or death by 26 percent in certain advanced kidney cancer cases

Clinical Trials
Roche announced results from the positive Phase III IMmotion151 study of TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) as a first-line treatment for advanced or metastatic...

Treatment and Management of Rare Lysosomal Diseases highlighted by shire at Global Conference

Clinical Trials
Shire plc  the global biotechnology leader in rare diseases, today announced that it will have 12 presentations, including 11 posters and one oral presentation,...

Positive Results from the Pivotal Phase III ‘OPTIMISMM’ Study of POMALYST/IMNOVID

Clinical Trials
Celgene Corporation announced that the Phase III, randomized, open-label, international clinical study, OPTIMISMM, achieved its primary endpoint, showing a statistically significant and clinically meaningful...

Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

Clinical Trials
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the first patient has been dosed in a phase 1 study evaluating the safety and...

Allergan Announces Positive Top Line Phase 3 Results for Ubrogepant – an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine.

Clinical Trials
Allergan plc , a leading global pharmaceutical company today announced positive results from ACHIEVE I (UBR-MD-01), the first of two pivotal phase 3 clinical...

Subscribe Our Newsletter

White Papers

The Future of Digital Health

Whitepapers 0
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

Five Best Practices to Deliver Exceptional Multichannel Experiences

Whitepapers 0
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

The Impact and Use of Social Media in Pharmacovigilance

Whitepapers 0
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...

About us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and
comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector. . . Read More

Resources

Advertise

Subscribe

Copyright © Value Media Group 2026. All rights reserved.